Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Inclusion Criteria: * If female and of childbearing potential, subject has a negative pregnancy test and is not nursing. * If female and of childbearing potential, subject is using adequate birth control for the duration of the study. * Subject is able to understand and comply with study procedures. * Subject is a non-smoker. * Subject consumes no more than 1 alcoholic drink per day. * Subject agrees to refrain from alcohol consumption for 48 hours prior to each drug administration and 48 hours after each drug administration. * Subject is able and willing to provide written informed consent prior to any study procedures being performed. Exclusion Criteria: * Subject has abnormal screening/baseline laboratory parameters deemed to be clinically significant by the Investigator. * Subject has taken any prescription medications other than hormone replacement therapy or thyroid replacement hormones within 3 days prior to drug administration. * Subject has taken any of the following medications within 2 weeks prior to study entry: * NSAIDs or other medications for pain, including aspirin or aspirin containing products and acetaminophen (see Appendix B of protocol in Appendix 16.1.1) * Proton pump inhibitors, including Prilosec®, Prevacid®, Aciphex®, Protonix®, or Nexium® * H-2 blockers, including Tagamet®, Zantac®, Axid®, or Pepcid® * Any antiplatelet agent, including Plavix®, Ticlid®, Pletal®, ReoPro®, Integrilin®, Aggrastat®, or Persantine® * Any anti-coagulant, including Coumadin®, Acenocoumarol, Phenprocoumon, Phenindione, Heparin, Exanta®, Argatroban, Lepirudin, Hirudin or Bivalirudin * Subject has used an investigational agent within the past 30 days. * Subject has hypersensitivity or contraindications to aspirin, ibuprofen, or other NSAID. * Subject has sensitivity to lecithin. * Subject has a history of gastrointestinal problems including ulcers, frequent indigestion, or heartburn. * Subject has a history of stroke, myocardial infarction, or congestive heart failure. * Subject has a history of asthma, other bronchospastic activity, nasal polyps, or angioedema other than resolved childhood asthma. * Subject has a history of kidney or liver disease. * Subject has a history of thrombocytopenia, neutropenia, or bleeding disorder. * Subject has a history of coronary arterial bypass. * Subject has a history of non-trauma related hemorrhage. * Subject has a history of chronic hypertension. * Subject is currently enrolled in another investigational trial. * Subject's platelets are unresponsive to arachidonic acid